SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Tajima N.)
 

Search: WFRF:(Tajima N.) > (2004) > JIKEI HEART Study--...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Mochizuki, S. (author)

JIKEI HEART Study--a morbi-mortality and remodeling study with valsartan in Japanese patients with hypertension and cardiovascular disease

  • Article/chapterEnglish2004

Publisher, publication year, extent ...

  • 2004

Numbers

  • LIBRIS-ID:oai:gup.ub.gu.se/56052
  • https://gup.ub.gu.se/publication/56052URI

Supplementary language notes

  • Language:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • BACKGROUND: Several recent clinical trials have demonstrated that angiotensin II receptor blockers (ARBs) have cardiovascular as well as renal protective effects. Asian patients including Japanese were under-represented in these trials, however, and no large-scale clinical trials of ARBs have yet been performed in Japan. It is therefore important to verify that the results of these studies are also valid for Japanese patients. The JIKEI HEART Study has been designed to investigate whether concomitant treatment with valsartan, an angiotensin II receptor blocker, in addition to conventional treatment, will improve the prognosis of Japanese patients with cardiovascular diseases (hypertension, ischemic heart disease, congestive heart failure). METHOD AND EVALUATION OF RESULTS: Around 3,000 patients with hypertension, ischemic heart disease and/or congestive heart failure will be randomized to receive either additional treatment with valsartan (80 mg/day) or conventional therapy. The follow-up period will be three years. The primary endpoint will be the onset of any cardiovascular event. Secondary endpoints will include death from any cause, changes in left ventricular size and function, renal function, changes in neuro-hormonal levels and quality-of-life assessments. Sub-studies will explore the effect in patients with diabetes mellitus, hyperlipidemia and the effects of combination of drugs. CONCLUSION: Improved prognosis would confirm the role of angiotensin II receptor blockers in the treatment of the cardiovascular disease in Japanese patients.

Subject headings and genre

  • Adult
  • Aged
  • Angiotensin II Type 1 Receptor Blockers/*therapeutic use
  • Antihypertensive Agents/*therapeutic use
  • Cardiovascular Diseases/*drug therapy/*mortality
  • Female
  • Follow-Up Studies
  • Heart Failure
  • Congestive/drug therapy/mortality
  • Humans
  • Hypertension/*drug therapy/*mortality
  • Japan/epidemiology
  • Male
  • Middle Aged
  • Myocardial Ischemia/drug therapy/mortality
  • Quality of Life
  • Receptors
  • Angiotensin/antagonists & inhibitors
  • Tetrazoles/*therapeutic use
  • Treatment Outcome
  • Valine/*analogs & derivatives/therapeutic use
  • Ventricular Function
  • Left/drug effects
  • Ventricular Remodeling/*drug effects

Added entries (persons, corporate bodies, meetings, titles ...)

  • Shimizu, M. (author)
  • Taniguchi, I. (author)
  • Kanae, K. (author)
  • Yoshida, S. (author)
  • Tajima, N. (author)
  • Dahlöf, Björn,1953Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute(Swepub:gu)xdahbj (author)
  • Göteborgs universitetHjärt-kärlinstitutionen (creator_code:org_t)

Related titles

  • In:Cardiovasc Drugs Ther18:4, s. 305-90920-3206

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view